ANVS logo

ANNOVIS BIO

ANVSNYSE
🏆 #4404 by market capUS Equity
$426.76▲ $27.01 (+6.33%)
Simulated price
🔔
Track ANVS
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 6.3%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$55M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
48
Weak
No chart data available for ANVS.

Trading Snapshot

Day Range
$423.40 – $434.32
52-Week Range
$1.04 – $5.50
Volume
$6.42B
Avg Volume
$5.64B
Shares Outstanding
34.6M
Next Earnings
Nov 11, 2026

Fundamentals Snapshot

Annual Revenue
$5M
Last Q Revenue
$1M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-1.78
Dividend Yield
—
Dilution (1yr)
+79.9%

Why Investors Own ANVS

  • ✓High-growth profile — revenue up -2.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 39% gross margin and 13% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ANVS logo

ANNOVIS BIO

ANVS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$30M▲ +11.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$26M▲ +17.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
24.8M▲ +79.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$20M▲ +$9M YoY
StockOtter · stockotter.space

About ANNOVIS BIO

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
48/100

Analyst Price Target

ⓘ
Average Target
$552.26
▲ +29.4% Upside
High Target$618.52
Low Target$465.97
Based on 14 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

ANNOVIS BIO tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift ANVS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

ANNOVIS BIO announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.